Results 1 - 2 of 2
Results 1 - 2 of 2. Search took: 0.01 seconds
|Sort by: date | relevance|
[en] To develop the immunoradiometric assay (IRMA) for tumor-associated trypsinogen-2 (TAT-2), and trying to apply it in cancer diagnosis, the anti-TAT-2 McAb T2C and T2L were used as catching and labeling antibody, respectively. The polystyrene beads were coated with McAb T2C to form solid phase in carbonate buffer of pH9.6; the McAb T2L was iodinated with 125I by chloramine-T. The different amounts of standard TAT-2 were reacted with solid phase McAb and 125I-labeled McAb to establish standard curve. The serum or urine TAT-2 levels of cancer patients and normal individuals were detected and compared with each other. Results showed that the Bmax/T was (22 ± 3.2)%, Bmax/B0 ratio was (689.2 ± 35.6)%, the non-specific binding rate was below 0.5%, and the low detected limit was 0.5 ng/mL. The within-assay CV was (4.3 ± 0.26)%, the between-assays CV was (10.6±1.2)%. The recoveries of detection of serum and urine TAT-2 were (98.5±3.1)% and (97.9±2.3)%, respectively. The TAT-2 value in normal individuals in sera (n=87) was 7.58 ± 5.46 ng/mL, and in urine (n=20) was 3.11 ± 1.62 ng/mL. The TAT-2 value in patients with gastric cancer in sera was 63.12 ± 62.9 ng/mL. The TAT-2 value in patients with pancreatic and bile duct cancers (n=12) in urine was 263.6 ± 185.3 ng/mL, and TAT-2 in patients with other metastatic cancers (n=16) in urine was 104.9 ± 171.2 ng/mL. The differences of TAT-2 levels between cancer patients and normal individuals were very significant (P<0.001 for all three groups). Therefore, the development of TAT-2 IRMA could provide a good indicator which should be very helpful in cancer diagnoses
[en] We have developed a murine model expressing the rhesus macaque (RM) Mamu-A*01 MHC allele to characterize immune responses and vaccines based on antigens of importance to human disease processes. Towards that goal, transgenic (Tg) mice expressing chimeric RM (α1 and α2 Mamu-A*01 domains) and murine (α3, transmembrane, and cytoplasmic H-2Kb domains) MHC Class I molecules were derived by transgenesis of the H-2KbDb double MHC Class I knockout strain. After immunization of Mamu-A*01/Kb Tg mice with rVV-SIVGag-Pol, the mice generated CD8+ T-cell IFN-γ responses to several known Mamu-A*01 restricted epitopes from the SIV Gag and Pol antigen sequence. Fusion peptides of highly recognized CTL epitopes from SIV Pol and Gag and a strong T-help epitope were shown to be immunogenic and capable of limiting an rVV-SIVGag-Pol challenge. Mamu-A*01/Kb Tg mice provide a model system to study the Mamu-A*01 restricted T-cell response for various infectious diseases which are applicable to a study in RM.